A phase I study of TRK-950 in patients with advanced solid tumors

Mori Yoshitaka0 个研究点目标入组 19 人开始时间: 2022年6月11日最近更新: 2024年5月27日

试验速览

暂无简介。

•Part 1: Patients with histologically and cytologically confirmed locally advanced or metastatic solid tumors who have been refractory or intolerant to standard therapies or for whom no standard therapy exists
•Part 2: Patients with histologically and cytologically confirmed locally advanced or metastatic solid tumors who are eligible for standard therapy with NIVO 240 mg alone administered at 2-week intervals.
•- Patients with life expectancy of at least 3 months after the start of study drug administration
•- Patients aged >=18 years at the time of consent
•- Patients who are able to provide written consent in person to be a subject of this study
•- A negative pregnancy test before enrollment (if female of childbearing potential)

•- Patients with active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
•- Pregnant women (including those who are considered possibly pregnant based on history taking, etc. by physician) or breastfeeding women (interrupting breastfeeding to enroll is also not allowed)
•- Patients who are unwilling or unable to comply with the protocol specified procedures
•- Patients who are positive for human immunodeficiency virus (HIV) antibody
•- Patients who meet any of the following conditions on hepatitis B virus (HBV) and hepatitis C virus (HCV) testing
•- Patients who are positive for hepatitis B surface antigen (HBsAg)
•- Patients who are positive for HCV RNA

发起方

Mori Yoshitaka